CA2007181A1 - Compose pharmaceutique a liberation continue - Google Patents

Compose pharmaceutique a liberation continue

Info

Publication number
CA2007181A1
CA2007181A1 CA2007181A CA2007181A CA2007181A1 CA 2007181 A1 CA2007181 A1 CA 2007181A1 CA 2007181 A CA2007181 A CA 2007181A CA 2007181 A CA2007181 A CA 2007181A CA 2007181 A1 CA2007181 A1 CA 2007181A1
Authority
CA
Canada
Prior art keywords
sustained release
release pharmaceutical
pharmaceutical composition
active ingredient
core element
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2007181A
Other languages
English (en)
Other versions
CA2007181C (fr
Inventor
Angelo Mario Morella
Mark Christopher Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2007181A1 publication Critical patent/CA2007181A1/fr
Application granted granted Critical
Publication of CA2007181C publication Critical patent/CA2007181C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA002007181A 1989-01-06 1990-01-04 Compose pharmaceutique a liberation continue Expired - Lifetime CA2007181C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ219289 1989-01-06
AUPJ2192 1989-01-06

Publications (2)

Publication Number Publication Date
CA2007181A1 true CA2007181A1 (fr) 1990-07-06
CA2007181C CA2007181C (fr) 1998-11-24

Family

ID=3773627

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002007181A Expired - Lifetime CA2007181C (fr) 1989-01-06 1990-01-04 Compose pharmaceutique a liberation continue

Country Status (10)

Country Link
EP (2) EP0377518B1 (fr)
JP (1) JP2937376B2 (fr)
AT (2) ATE133862T1 (fr)
CA (1) CA2007181C (fr)
DE (2) DE69032445T2 (fr)
DK (2) DK0377518T3 (fr)
ES (2) ES2120562T3 (fr)
GR (1) GR3019201T3 (fr)
HK (1) HK154296A (fr)
NZ (1) NZ232029A (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
GB2281204A (en) * 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
GB2288117A (en) * 1994-03-01 1995-10-11 Euro Celtique Sa Sustained release morphine
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
ZA937382B (en) * 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP1442745A1 (fr) * 1993-10-07 2004-08-04 Euro-Celtique Compositions d'opioides pour administration orale ayant un effet prolongé
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
AT403988B (de) * 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US6491945B1 (en) * 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
PT946151E (pt) * 1996-11-25 2006-07-31 Alza Corp Forma de dosagem de dose crescente
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
PT1009387E (pt) 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
JP2001526228A (ja) * 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
EP1207860B1 (fr) * 1999-09-02 2007-10-24 Nostrum Pharmaceuticals, Inc. Formulation de type pastille a liberation controlee
WO2001019901A2 (fr) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Procede relatif a la formation de granules a revetement aqueux
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2002003366A (ja) * 2000-06-23 2002-01-09 Freunt Ind Co Ltd 固形薬剤用水系コーティング剤組成物
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
DK2153819T3 (da) 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
IL151530A0 (en) 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
AU2738302A (en) * 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
CA2540308C (fr) 2003-09-26 2013-08-06 Alza Corporation Enrobage de medicaments a charge medicamenteuse elevee et procedes de fabrication
WO2005046655A1 (fr) * 2003-11-04 2005-05-26 Shire Laboratories, Inc. Liberation prolongee de molecules actives d'un point de vue pharmacologique positivement chargees a partir d'une matrice contenant des polymeres avec des atomes d'oxygene polarises
EP1879557A1 (fr) * 2005-05-13 2008-01-23 Alpharma, Inc. Formulations de sulfate de morphine
WO2006124890A1 (fr) * 2005-05-13 2006-11-23 Alpharma, Inc. Formulations de sulfate de morphine
CA2617164A1 (fr) * 2005-08-01 2007-02-08 Alpharma Inc. Formulations pharmaceutiques resistantes a l'alcool
EP1915137B8 (fr) 2005-08-10 2013-09-11 ADD Advanced Drug Delivery Technologies, Ltd. Préparation orale à libération contrôlée
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
JP5457830B2 (ja) * 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
FR2951378B1 (fr) * 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
MY161846A (en) 2010-07-09 2017-05-15 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
US20120251588A1 (en) * 2011-03-30 2012-10-04 Miyuki Fukasawa Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation
EP2606879A1 (fr) 2011-12-21 2013-06-26 Hexal AG Formule de comprimé en pastille d'unité multiple contenant un opioïde
CA2910865C (fr) 2014-07-15 2016-11-29 Isa Odidi Compositions et methodes destines a reduire les surdoses
US20170182070A1 (en) * 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2017223402A1 (fr) 2016-06-23 2017-12-28 Corium International, Inc. Matrice adhésive à un domaine hydrophile, un domaine hydrophobes et un agent thérapeutique
CN116270551A (zh) * 2016-07-27 2023-06-23 考里安有限责任公司 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
US10765635B2 (en) 2018-02-06 2020-09-08 Nano Pharmaceutical Laboratories Llc Multiparticulate including pharmaceutical or probiotic active ingredients for delivery via a shelf stable liquid dosage form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
EP0327295A3 (fr) * 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Forme de dosage de la tétracycline

Also Published As

Publication number Publication date
EP0609961B1 (fr) 1998-06-24
EP0377518B1 (fr) 1996-02-07
GR3019201T3 (en) 1996-06-30
EP0377518A3 (en) 1990-10-24
ATE133862T1 (de) 1996-02-15
DE69025208T2 (de) 1996-06-13
DE69025208D1 (de) 1996-03-21
ES2120562T3 (es) 1998-11-01
EP0609961A1 (fr) 1994-08-10
DE69032445D1 (de) 1998-07-30
ATE167629T1 (de) 1998-07-15
AU617573B2 (en) 1991-11-28
AU4773290A (en) 1990-07-12
HK154296A (en) 1996-08-16
JPH032114A (ja) 1991-01-08
DK0377518T3 (da) 1996-06-24
ES2085886T3 (es) 1996-06-16
JP2937376B2 (ja) 1999-08-23
CA2007181C (fr) 1998-11-24
DE69032445T2 (de) 1999-02-18
NZ232029A (en) 1992-04-28
EP0377518A2 (fr) 1990-07-11
DK0609961T3 (da) 1999-04-06

Similar Documents

Publication Publication Date Title
CA2007181A1 (fr) Compose pharmaceutique a liberation continue
EP0377517A3 (fr) Forme de dose de théophylline
SE9202250D0 (sv) Controlled release morphine preparation
IE872924L (en) Controlled release oral dosage form
GB2264640B (en) Microcrystalline cellulose spheroids comprising hydromorphone and a sugar
EP0974350A4 (fr) Preparation a usage externe comprenant du tranilast et processus de production de cette preparation
EP0391002A3 (fr) Compositions pharmaceutiques contenant de l'acide anthranilique N-(3-4-diméthoxycinnamoyl)
GR3005035T3 (fr)
CA2190303A1 (fr) Composition pharmaceutique; methode et dispositif pour prevenir ou traiter le syndrome sec ou les maladies qui en decoulent
MY104006A (en) 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases.
AU4434389A (en) Aqueous oral pharmaceutical preparation of diclofenac
CA2132528A1 (fr) Agent utilise comme anti-irritant
CA2244679A1 (fr) Preparation contenant du tranilast pour application externe et methode de production de cette preparation
EP0332295A3 (fr) Dérivés d'imidazole
AU581368B2 (en) Agent for preventing the accumulation of sorbitol in a living body, which comprises a derivative of aminobenzoic acid
IT1255237B (it) Composizione farmaceuticaidrofila ad attivita' antiinfiammatoria
HUT59795A (en) Selective herbicide compositions containing arene-sulfonyl-cyclic-guanidine derivatives as active components and process for producing the active components

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry